Top

Journal of General Internal Medicine

Published in:

01-09-2008

Revisiting the Duration of Vasomotor Symptoms of Menopause: A Meta-Analysis

Authors: Mary C. Politi, Ph.D, Mark D. Schleinitz, M.D., M.S., Nananda F. Col, M.D., M.P.P., M.P.H., F.A.C.P.

Published in: Journal of General Internal Medicine | Issue 9/2008

Abstract

Background

Treatment decisions about menopause are predicated on a transient duration of vasomotor symptoms. However, evidence supporting a specific duration is weak.

Objective

To estimate the natural progression of vasomotor symptoms during the menopause transition by systematically compiling available evidence using meta-analytic techniques.

Data Sources

We searched MEDLINE, hand searched secondary references in relevant studies, book chapters, and review papers, and contacted investigators about relevant published research.

Review Methods

English language, population-based studies reporting vasomotor symptom prevalence among women in menopausal transition in time intervals based on years to or from final menstrual period were included. Two reviewers independently assessed eligibility and quality of studies and extracted data for vasomotor symptom prevalence.

Results

The analyses included 10 studies (2 longitudinal, 8 cross sectional) with 35,445 participants. The percentage of women experiencing symptoms increased sharply in the 2 years before final menstrual period, peaked 1 year after final menstrual period, and did not return to premenopausal levels until about 8 years after final menstrual period. Nearly 50% of all women reported vasomotor symptoms 4 years after final menstrual period, and 10% of all women reported symptoms as far as 12 years after final menstrual period. When data were examined according to symptom severity (‘any’ vs. ‘bothersome’), bothersome symptoms peaked about 1 year earlier and declined more rapidly than symptoms of any severity level.

Conclusions

Our findings suggest a median symptom duration of about 4 years among symptomatic women. A longer symptom duration may affect treatment decisions and clinical guidelines. Further prospective, longitudinal studies of menopausal symptoms should be conducted to confirm these results.

Available only for authorised users

McKinlay SM, Brambilla DJ, Posner JG. The normal menopause transition. Maturitas. 1992;14(2):103–15.PubMedCrossRef

Guthrie J, Dennerstein L, Taffe J, Donnelly V. Health care-seeking for menopausal problems. Climacteric. 2003;6(2):112–7.PubMedCrossRef

Lobo R (ed). Treatment of the postmenopausal woman: Basic and clinical aspects.: Academic Press; 2007.

Medical Knowledge Self Assessment Program 14. 2007.

North American Menopause Society. Treatment of menopause-associated vasomotor symptoms: Position statement of The North American Menopause Society. Menopause. 2004;11:11–33.CrossRef

Kronenberg F. Hot flashes: epidemiology and physiology. Ann N Y Acad Sci. 1990;592:52–86. discussion 123–33.PubMedCrossRef

Col NF. The impact of risk status, preexisting morbidity, and polypharmacy on treatment decisions concerning menopausal symptoms. Am J Med. 2005;118(12 Suppl 2):155–62.PubMedCrossRef

Rossouw JE, Prentice RL, Manson JE, et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA. 2007;297(13):1465–77.PubMedCrossRef

Women’s Health Initiative. Scientific Resources Website. Vol. 2006.

10.

Grodstein F, Clarkson TB, Manson JE. Understanding the divergent data on postmenopausal hormone therapy. The New England Journal of Medicine. 2003;348(7):645–50.PubMedCrossRef

11.

American College of Obstetricians and Gynecologists. Executive Summary. Hormone Therapy. Obstetrics & Gynecology. 2004;104:1S.CrossRef

12.

Mosca L, Collins P, Herrington DM, et al. Hormone Replacement Therapy and cardiovascular disease: A statement for healthcare professionals from the American Heart Association. Circulation. 2001;104:499–503.PubMedCrossRef

13.

Grady D. Management of menopausal symptoms. The New England Journal of Medicine. 2006;355(22):2338–47.PubMedCrossRef

14.

National Institute of Health. NIH State-of-the-Science conference on management of menopause-related symptoms. Vol. 2005; 2005.

15.

Woods NF, Mitchell ES. Symptoms during the perimenopause: Prevalence, severity, trajectory, and significance in women’s lives. Am J Med. 2005;118(12B):14S–24S.CrossRef

16.

Medical Women’s Federation. An investigation of the menopause in one thousand women. The Lancet. 1933:106–108.

17.

Feldman BM, Voda A, Gronseth E. The prevalence of hot flash and associated variables among perimenopausal women. Res Nurs Health. 1985;8(3):261–8.PubMed

18.

Kronenberg F. Hot Flashes. New York: Raven Press, Ltd.; 1994:97.

19.

Association for Healthcare Research and Quality. Evidence report/Technology assessment: Management of menopause-related symptoms. Vol. 2005; 2005.

20.

Wells GA, Shea B, O’Connell D, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. 2000.

21.

McKinlay SM, Jefferys M. The menopausal syndrome. Br J Prev Soc Med. 1974;28(2):108–15.PubMed

22.

Oldenhave A, Jaszmann LJ, Haspels AA, Everaerd WT. Impact of climacteric on well-being. A survey based on 5213 women 39 to 60 years old. Am J Obstet Gynecol. 1993;168(3 Pt 1):772–80.PubMed

23.

Thompson B, Hart SA, Durno D. Menopausal age and symptomatology in a general practice. J Biosoc Sci. 1973;5(1):71–82.PubMedCrossRef

24.

Berg G, Gottwall T, Hammar M, Lindgren R. Climacteric symptoms among women aged 60–62 in Linkoping, Sweden, in 1986. Maturitas. 1988;10(3):193–9.PubMedCrossRef

25.

Nedstrand E, Pertl J, Hammar M. Climacteric symptoms in a postmenopausal Czech population. Maturitas. 1996;23(1):85–9.PubMedCrossRef

26.

Avis NE, Brockwell S, Colvin A. A universal menopausal syndrome? Am J Med. 2005;118(12 Suppl 2):37–46.PubMedCrossRef

27.

Brown WJ, Mishra GD, Dobson A. Changes in physical symptoms during the menopause transition. Int J Behav Med. 2002;9(1):53–67.PubMedCrossRef

28.

Groenveld FPMJ, Bareman FP, Barentsen , Dokter HJ, Drogendijk AC, Hoes AW. Vasomotor symptoms and the well–being in the climacteric years. Maturitas. 1996;23:293–9.CrossRef

29.

Melby MK. Vasomotor symptom prevalence and language of menopause in Japan. Menopause: The Journal of the North American Menopause Society. 2005;12(3):250–7.

30.

Soules M, Sherman S, Parrott E, et al. Executive summary: Stages of Reproductive Aging Workshop (STRAW). Climacteric. 2001;4(4):267–72.PubMedCrossRef

31.

Genazzani A, Nicolucci A, Campagnoli C, et al. Validation of Italian version of the Women’s Health Questionnaire: Assessment of quality of life of women from the general population and those attending menopause centers. Climacteric. 2002;5:70–7.PubMedCrossRef

32.

Binfa L, Castelo-Branco C, Blumel JE, et al. Influence of psychosocial factors on climacteric symptoms. Maturitas. 2004;48:425–31.PubMedCrossRef

33.

Travers C, O’Neill SM, King , Battistutta D, Khoo SK. Greene Climacteric Scale: Norms in an Australian population in relation to age and menopausal status. Climacteric. 2005;8:56–62.PubMedCrossRef

34.

Ford K, Sowers MF, Crutchfield M, Wilson A, Jannausch M. A longitudinal study of the predictors of prevalence and severity of symptoms commonly associated with menopause. Menopause: The Journal of the North American Menopause Society. 2005;12(3):308–17.

35.

Stroup DF, Berlin JA, Morton SC, et al. Meta analysis of observational studies in epidemiology: A proposal for reporting. JAMA. 2000;283(15):2008–20012.PubMedCrossRef

36.

Lau J. Metaanalyst. Boston, MA, US.

37.

DerSimonian , Laird N. Meta-analysis in Clinical Trials. Control Clin Trials. 1986;7:177–88.PubMedCrossRef

38.

Kaufert P, Syrotuik J. Symptom reporting at the menopause. Soc Sci Med. 1981;15(3):173–84.

39.

Hunter M. The south-east England longitudinal study of the climacteric and postmenopause. Maturitas. 1992;14(2):117–26.PubMedCrossRef

40.

Bardel A, Wallander M-A, Svardsudd K. Hormone replacement therapy and symptom reporting in menopausal women. A population-based study of 35–65 year old women in mid-Sweden. Maturitas. 2002;41:7–15.PubMedCrossRef

41.

Overlie I, Finset A, Holte A. Gendered personality dispositions, hormone values, and hot flushes during and after menopause. J Psychosom Obstet Gynaecol. 2002;23:219–27.PubMedCrossRef

42.

Keenan NL, Mark S, Fugh-Berman A, Browne D, Kaczmarczyk J, Hunter C. Severity of menopausal symptoms and use of both conventional and complementary/alternative therapies. Menopause: The Journal of the North American Menopause Society. 2003;10(6):507–15.

43.

Juang KD, Wang SJ, Lu S, Lee SJ, Fuh JL. Hot flashes are associated with psychological symptoms of anxiety and depression in peri- and post- but not premenopausal women. Maturitas. 2005;52(2):119–26.PubMedCrossRef

44.

Kumari M, Stafford M, Marmot M. The menopausal transition was associated in a prospective study with decreased health functioning in women who report menopausal symptoms. J Clin Epidemiol. 2005;58(7):719–27.PubMedCrossRef

45.

Miller S, Gallicchio LM, Lewis LM, et al. Association between race and hot flashes in midlife women. Maturitas. 2006;54:260–9.PubMedCrossRef

46.

Sievert LL, Obermeyer CM, Price K. Determinants of hot flashes and night sweats. Ann Hum Biol. 2006;33(1):4–16.PubMedCrossRef

47.

Huang AJ, Grady DG, Blackwell TL, Bauer DC, Sawaya GF. Persistent hot flashes in older postmenopausal women (abstract). J Gen Intern Med. 2007;22(suppl 1):168.

48.

Guthrie J, Dennerstein L, Taffe J, Lehert P, Burger HG. Hot flushes during the menopause transition: a longitudinal study in Australian-born women. Menopause. 2005;12(4):460–7.PubMedCrossRef

49.

Warren MP. Historical perspectives in postmenopausal hormone therapy: Defining the right dose and duration. Mayo Clinic Proceedings. 2007;82(2):219–26.PubMedCrossRef

50.

Gold EB, Sternfeld B, Kelsey JL, et al. Relation of demographic and lifestyle factors to symptoms in a multi-racial/ethnic population of women 40–55 years of age. Am J Epidemiol. 2000;152(5):463–73.PubMedCrossRef

51.

Avis NE, Crawford SL, McKinlay SM. Psychosocial, behavioral, and health factors related to menopause symptomatology. Womens Health. 1997;3(2):103–20.PubMed

52.

Avis NE, Stellato , Crawford S, et al. Is there a menopausal syndrome? Menopausal status and symptoms across racial/ethnic groups. Soc Sci Med. 2001;52(3):345–56.PubMedCrossRef

53.

Avis NE, Zhao X, Johannes CB, Ory M, Brockwell S, Greendale GA. Correlates of sexual function among multi-ethnic middle-aged women: results from the Study of Women’s Health Across the Nation (SWAN). Menopause. 2005;12(4):385–98.PubMedCrossRef

Title: Revisiting the Duration of Vasomotor Symptoms of Menopause: A Meta-Analysis
Authors: Mary C. Politi, Ph.D
Mark D. Schleinitz, M.D., M.S.
Nananda F. Col, M.D., M.P.P., M.P.H., F.A.C.P.
Publication date: 01-09-2008
Publisher: Springer-Verlag
Published in: Journal of General Internal Medicine / Issue 9/2008
Print ISSN: 0884-8734
Electronic ISSN: 1525-1497
DOI: https://doi.org/10.1007/s11606-008-0655-4

ACC 2024 Congress Coverage

Heart Failure Video

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Revisiting the Duration of Vasomotor Symptoms of Menopause: A Meta-Analysis

Abstract

Background

Objective

Data Sources

Review Methods

Results

Conclusions

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Background

Objective

Data Sources

Review Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 9/2008

Self-Reported Peripheral Arterial Disease Predicts Future Vascular Events in a Community-Based Cohort

Quality of Care for Decompensated Heart Failure: Comparable Performance between Academic Hospitalists and Non-hospitalists

I’m Dreaming of Walt Whitman

An Unusual Case of Hematochezia: Acute Ischemic Proctosigmoiditis

A Profile of Concurrent Alcohol and Alcohol-Interactive Prescription Drug Use in the US Population

Substituted Judgment: The Limitations of Autonomy in Surrogate Decision Making

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page